Amgen delivered solid Q3 results with a 12% revenue increase and raised its non-GAAP EPS guidance, demonstrating resilience amid COVID-19 challenges. Strong performance in key products like Repatha and a robust pipeline enhance investor confidence, likely supporting a positive short-term stock movement.

[1]